The role of the endocannabinoid pathway in metabolism and diabetes

Current Opinion in Endocrinology and Diabetes

Volumn 13, Issue 2, 2006, Pages 171-178

  Pagotto, Uberto ^a   Pasquali, Renato ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cannabinoid type 1 receptor; Endocannabinoids; Rimonabant; Visceral obesity

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; RIMONABANT;

ADIPOSE TISSUE; AGITATION; ANXIETY DISORDER; APPETITE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; FOOD INTAKE; HUMAN; HYPOTHALAMUS; LIMBIC SYSTEM; LIVER; METABOLIC DISORDER; METABOLIC REGULATION; NAUSEA; NONHUMAN; OBESITY; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; VOMITING;

EID: 33646038290     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000216966.36504.65     Document Type: Review

References (44)

1. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561-564.
2. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54:161-202.
3. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50:83-90.
4. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258:1946-1949.
5. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215:89-97.
6. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004; 141:765-774.
7. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4:873-884.
8. van der Stelt M, Veldhuis WB, Maccarrone M, et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 2002; 26:317-346.
9. Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 2004; 61:149-160.
10. Wotjak CT. Role of endogenous cannabinoids in cognition and emotionality. Mini Rev Med Chem 2005; 5:659-670.
11. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418:530-534.
12. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2005; Nov 23 [Epub ahead of print]. A complete revision of all the phyisological and pathological implications of exogenous and endogenous cannabinoids in endocrinology and metabolism.
13. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8:585-589.
14. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005; 76:1307-1324.
15. Lange JH, Kruse CG. Recent advances in CB1 cannabinoid receptor antagonists. Curr Opin Drug Discov Devel 2004; 7:498-506.
16. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350:240-244.
17. Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of effects of smoked marijuana by the CB1 -selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58:322-328.
18. Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004; 161:975-984.
19. Anthenelli RM, Despres JP. Effects of rimonabant in the reduction of major cardiovascular risk factors results from the STRATUS-US trial (smoking cessation in smokers motivated to quit) [abstract]. Program of the 53rd Annual Scientific Session of the American College of Cardiology; March 2004; New Orleans.
20. Boyd ST, Fremming BA. Rimonabant: a selective CB1 antagonist. Ann Pharmacother 2005; 39:684-690.
21. Fernandez JR, Allison DB. Rimonabant Sanofi-Synthelabo. Curr Opin Invest Drugs 2004; 5:430-435.
22. Third Report of the National Cholesterol Educational Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421
23. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365:1389-1397. The results of the first phase III trial, in which rimonabant was given to obese or overweight patients.
24. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121-2134. The results of the second phase III trial, in which rimonabant was given to obese or overweight patients with dyslipidemia.
25. Yanovski SZ. Pharmacotherapy for obesity: promise and uncertainty. N Engl J Med 2005;353:2187-2189.
26. Cota D, Marsicano G, Tschoep M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112:423-431.
27. Ravinet-Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284:R345-R353.
28. Ravinet-Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28:640-648.
29. Arnone M, Maruani J, Chaperon F, et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997; 132:104-106.
30. Gallate JE, Saharov T, Mallet PE, McGregor IS. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur J Pharmacol 1999; 370:233-240.
31. Freedland CS, Poston JS, Porrino LJ. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 2000; 67:265-270.
32. Simiand J, Keane M, Keane PE, Soubrié P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998; 9:179-181.
33. Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 2005; 16:297-313.
34. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410:822-825.
35. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63:908-914.
36. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes Relat Metab Disord 2005; 29:183-187.
37. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115:1298-1305. In this brilliant publication, the physiological and pathophysiological role of endocannabinoids in hepatocytes were elucidated for the first time.
38. Vickers SP, Webster LJ, Wyatt A, et al. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared with lean Zucker rats. Psychopharmacology (Berl) 2003; 167:103-111.
39. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19:1567-1569. This key study demonstrated the ability of rimonabant in adipose tissue to modulate clusters of genes involved in several metabolic functions.
40. Toth PP. Adiponectin and high-density lipoprotein: a metabolic association through thick and thin. Eur Heart J 2005; 26:1579-1581. An exhaustive overview of the actions of adiponectin.
41. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1:15-25.
42. Baratta R, Amato S, Degano C, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 2004; 89:2665-2671.
43. Cote M, Mauriege P, Bergeron J, et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005; 90:1434-1439.
44. von Eynatten M, Schneider JG, Humpert PM, et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 2004; 27:2925-2929.